CYP17A1¹¹ CYP17A1
cytochrome P450 17A1, encoding the bifunctional enzyme 17α-hydroxylase/17,20-lyase sits at one of the most critical branch points in human steroid biosynthesis. The enzyme converts pregnenolone and progesterone to 17-hydroxy intermediates (generating cortisol precursors) and catalyzes the subsequent lyase reaction that produces DHEA and androstenedione — the precursors to all androgens and estrogens. rs6162 is a synonymous coding variant at codon 46 of CYP17A1 (c.138C>T, His46=), meaning it does not change the encoded amino acid. Its biological significance is primarily as a haplotype-tagging SNP: it co-occurs in strong linkage disequilibrium with the 5'UTR variant rs743572 (T-34C)²² rs743572 (T-34C)
rs743572 lies 171 bp upstream of rs6162 and creates an Sp1 transcription factor binding site that alters CYP17A1 promoter activity, and the rs6162 A allele effectively tags the CYP17A1 haplotype associated with altered enzyme expression and steroid output.

The Mechanism

The rs6162 A allele (synonym: the CAT codon at position 46 vs. the reference CAC codon; both encode histidine) does not directly alter CYP17A1 protein function. Rather, it resides in strong LD with regulatory variants in the CYP17A1 locus — most notably rs743572 (T-34C), which creates an additional Sp1 binding site in the promoter region and is associated with increased transcription of the enzyme in some in vitro systems. Variants in this haplotype block influence how much CYP17A1 protein is produced, altering flux through the 17α-hydroxylase and 17,20-lyase reactions. The lyase step is rate-limiting for DHEA synthesis; increased CYP17A1 activity pushes more steroid substrate toward the Δ5 pathway³³ Δ5 pathway
the androgen biosynthesis pathway through DHEA and androstenedione, as opposed to the Δ4 glucocorticoid pathway and away from cortisol precursors. The downstream effects include elevated DHEA-S and, through peripheral conversion, raised androgen levels — an effect directly relevant to prostate cancer biology and androgen signaling in general.

The Evidence

The most rigorous study of rs6162 is Lévesque et al. 2013 in Clinical Cancer Research⁴⁴ Lévesque et al. 2013 in Clinical Cancer Research
Molecular markers in key steroidogenic pathways, circulating steroid levels, and prostate cancer progression. Clin Cancer Res 19:699–709, which genotyped 109 haplotype-tagging SNPs across CYP17A1, ESR1, CYP19A1, and HSD3B1 in 526 Caucasian men with organ-confined prostate cancer and validated findings in 601 Taiwanese men on androgen-deprivation therapy. After adjusting for known risk factors, CYP17A1 rs6162 was significantly associated with disease progression in both cohorts — hazard ratios of 2.29–4.10 in the Caucasian group (P=0.0014 to 2×10⁻⁷) and HR 3.74 (95% CI 1.71–8.19, P=0.009) in the Taiwanese group. Critically, the rs6162 polymorphism was also linked to plasma DHEA-S levels in Caucasian men (P=0.03), providing a plausible biochemical mechanism: the haplotype tagged by rs6162 influences adrenal androgen output, and elevated DHEA-S fuels intratumoral androgen synthesis even during castration.

Yamada et al. 2013 in Int J Clin Oncol⁵⁵ Yamada et al. 2013 in Int J Clin Oncol
CYP17A1 polymorphisms associated with risk of CRPC in Japanese men receiving ADT. Int J Clin Oncol 18:711–717 examined 214 Japanese men on hormone therapy and found that rs6162 (among three other CYP17A1 SNPs: rs743572, rs6163, rs1004467) was significantly associated with castration-resistant prostate cancer progression (P<0.05). This cross-ethnic replication — in a population with a 54% A allele frequency versus ~41% in Europeans — strengthens the evidence for a functional role of this haplotype.

Robles-Fernandez et al. 2017 in PLoS One⁶⁶ Robles-Fernandez et al. 2017 in PLoS One
Polymorphisms in sex hormone synthesis and metabolism genes and prostate cancer aggressiveness. PLoS One 12:e0185447 genotyped 311 Caucasian men and found the G allele of rs6162 was associated with PSA levels >10 ng/mL, while the AG+AA genotype group showed association with higher D'Amico risk stratification — suggesting the variant may influence both hormone levels and clinical tumor phenotype.

More recently, Hahn et al. 2025 in Prostate Cancer Prostatic Dis⁷⁷ Hahn et al. 2025 in Prostate Cancer Prostatic Dis
Body composition as a determinant of the therapeutic index with androgen signaling inhibition. Prostate Cancer Prostatic Dis 28:802–808 found CYP17A1 rs6162 among three androgen synthesis gene polymorphisms associated with baseline body composition differences (adiposity) in 186 metastatic CRPC patients on ADT — suggesting the variant's influence on steroid synthesis extends to body composition phenotypes during androgen suppression.

Practical Actions

For men with the A allele, the key implication is altered DHEA-S production and downstream androgen availability. Even in the context of ADT, residual adrenal DHEA-S can be peripherally converted to testosterone and DHT, fueling continued prostate cancer signaling. Measuring baseline DHEA-S provides a direct readout of adrenal androgen output relevant to this haplotype. Abiraterone acetate (a potent CYP17A1 inhibitor) is specifically designed to block this residual adrenal androgen production in CRPC; men with the rs6162 A allele who progress to CRPC may be particularly suited to this mechanism of action.

For the broader reproductive hormones category, altered DHEA-S levels affect both sexes: in women, elevated adrenal DHEA-S is a contributor to androgen excess in PCOS-like phenotypes; in men, it fuels testosterone synthesis throughout life.

Interactions

rs6162 forms a haplotype with rs743572 (T-34C, 5'UTR), rs6163, and rs1004467 within the CYP17A1 locus. The rs743572 variant is the most studied regulatory element in this block and has the broadest literature on breast cancer, endometriosis, and PCOS risk. Studies examining rs6162 frequently co-report rs743572 results; the two SNPs are functionally inseparable in many population analyses. The combined haplotype, more than any individual SNP, determines CYP17A1 expression level and steroid output phenotype.

Your skin is not just packaging — it is an active immune organ, and at its center sits filaggrin. The FLG gene encodes profilaggrin¹¹ profilaggrin
a massive precursor protein cleaved into 10–12 filaggrin monomers during terminal differentiation of the epidermis, the protein responsible for aggregating keratin filaments into the dense, waterproof matrix of the outermost skin layer (stratum corneum). Filaggrin is then broken down into natural moisturizing factor (NMF)²² natural moisturizing factor (NMF)
a mixture of amino acids, urocanic acid, pyrrolidone carboxylic acid, urea, and ions that maintains stratum corneum hydration and regulates skin pH. The R501X variant (c.1501C>T) introduces a premature stop codon at position 501 of the protein, eliminating filaggrin production entirely from that allele — making it the most consequential single-nucleotide skin barrier variant known³³ the most consequential single-nucleotide skin barrier variant known
FLG loss-of-function mutations represent the strongest identified genetic risk factor for atopic dermatitis and ichthyosis vulgaris.

The Mechanism

Filaggrin haploinsufficiency (one non-functional copy) substantially reduces filaggrin protein levels, directly impairing barrier assembly and NMF production. The downstream consequences cascade across multiple systems. Without adequate NMF, transepidermal water loss (TEWL) increases, stratum corneum hydration falls, and skin pH rises above the optimal acidic range (pH 4.5–5.5). An alkaline skin surface dysregulates serine protease activity, accelerates corneocyte shedding, and impairs the acidic mantle's natural suppression of Staphylococcus aureus colonization. Structural gaps between corneocytes allow environmental allergens — house dust mite, pollen, food proteins⁴⁴ house dust mite, pollen, food proteins
Percutaneous sensitization through the defective barrier is the primary route for IgE sensitization and food allergy in FLG-null carriers — to penetrate into the viable epidermis, triggering IgE sensitization and Th2-skewed immune responses. This is the molecular foundation of the "atopic march."

The Evidence

R501X was identified in 2006 as the primary cause of ichthyosis vulgaris⁵⁵ ichthyosis vulgaris
a common inherited skin condition causing fish-scale dryness and rough skin and simultaneously as a major predisposing factor for atopic dermatitis⁶⁶ major predisposing factor for atopic dermatitis. The inheritance pattern is semidominant: heterozygotes show mild or no ichthyosis but substantially elevated eczema risk, while homozygotes and compound heterozygotes (carrying R501X on one chromosome and another FLG null allele such as 2282del4 on the other) exhibit overt ichthyosis and severe eczema.

A meta-analysis of 11 studies⁷⁷ meta-analysis of 11 studies
Baurecht et al. 2007: meta-analysis confirming OR 4.09 for FLG null mutations and atopic eczema from case-control studies established the odds ratio for atopic eczema as 4.09 (95% CI 2.64–6.33) from case-control data and 2.06 (95% CI 1.76–2.42) from family studies. A subsequent meta-analysis of 24 studies⁸⁸ meta-analysis of 24 studies
Rodríguez et al. 2009: FLG mutations are robust risk factors for eczema (OR 3.12) and eczema-associated asthma (OR 3.29) confirmed eczema risk (OR 3.12; 95% CI 2.57–3.79) and found that asthma risk is primarily driven by the eczema-asthma compound phenotype (OR 3.29; 95% CI 2.84–3.82), supporting percutaneous sensitization as the dominant mechanism.

FLG carriers face an elevated risk of eczema herpeticum⁹⁹ eczema herpeticum
a severe, potentially life-threatening herpes simplex virus infection of eczematous skin — the frequency of R501X was three times higher in eczema herpeticum patients than in eczema patients without this complication (25% vs 9%, OR 3.4). The variant also promotes Staphylococcus aureus colonization through impaired antimicrobial peptide function and disrupted skin pH.

A randomized controlled trial¹⁰¹⁰ randomized controlled trial
Simpson et al. 2014 JACI: daily emollient from birth reduced cumulative AD incidence by 50% in high-risk infants over 6 months demonstrated that daily emollient application from birth reduced cumulative atopic dermatitis incidence by approximately 50% in high-risk infants — providing direct evidence that barrier augmentation can interrupt the atopic march at its earliest stage.

Practical Actions

The central actionable insight from R501X carrier status is that the skin barrier needs external support that a non-carrier's skin provides internally. For carriers with existing eczema, ceramide-dominant emollients containing the physiologic 3:1:1 ratio of ceramides to cholesterol to free fatty acids most closely replicate what a functional stratum corneum would produce. Urea-containing emollients (10–25% urea) are specifically beneficial because urea is both an NMF component and promotes residual FLG expression — addressing the deficit from two angles. Fragrance, preservatives (especially methylisothiazolinone), and sodium lauryl sulfate in skincare products all exacerbate barrier disruption disproportionately in FLG carriers and should be avoided.

Heterozygous carriers who are not currently eczematous should consider proactive moisturizing during skin stress periods (low humidity, cold weather, frequent handwashing, swimming) to prevent barrier compromise that could initiate sensitization.

For parents carrying R501X: early, consistent emollient use in newborns at family risk is supported by RCT evidence for eczema prevention. Early oral introduction of allergenic foods (peanut, egg) — consistent with current LEAP-trial-informed guidelines — is particularly important in FLG carrier families because percutaneous sensitization through the defective barrier precedes oral tolerance and can establish food allergy before intentional food introduction.

Interactions

The two most common European FLG loss-of-function variants, R501X (rs61816761) and 2282del4 (rs558269137), interact as compound heterozygotes. An individual carrying one copy of each on separate chromosomes has no functional FLG gene — equivalent to homozygosity — and shows the most severe phenotype: overt ichthyosis vulgaris, high-penetrance eczema, and substantially elevated asthma risk. This compound heterozygous state is the most clinically significant FLG interaction.

Interaction between FLG null carrier status and early food sensitization creates a synergistic effect on asthma risk that exceeds the sum of independent effects. This means that preventing IgE food sensitization (through early allergen introduction) in FLG-carrier infants is particularly high-impact.

If both R501X (rs61816761) and 2282del4 (rs558269137) are carried — one on each chromosome — the individual is compound heterozygous and effectively FLG-null, with complete filaggrin absence. This is the most severe FLG genotype and warrants intensive daily ceramide-dominant emollient therapy (twice daily minimum), dermatology referral for personalized management, proactive monitoring for eczema herpeticum, early allergen introduction in offspring, and strict avoidance of all barrier-disrupting personal care ingredients (fragrance, methylisothiazolinone, sodium lauryl sulfate, propylene glycol).

Every red blood cell that reaches the end of its 120-day lifespan releases haemoglobin, which breaks down into biliverdin and then bilirubin¹¹ bilirubin
a yellow pigment that must be conjugated with glucuronic acid by UGT1A enzymes to become water-soluble and excretable in bile. The UGT1A gene cluster on chromosome 2q37 encodes nine UDP-glucuronosyltransferase enzymes — UGT1A1 through UGT1A10 — all sharing exons 2–5 but each with a unique exon 1 that confers distinct substrate preferences. rs6742078 sits in an intronic region of UGT1A10, near the 3′ end of the cluster (chr2:233,763,993, GRCh38), but the variant's GWAS signal spans the entire cluster and tracks most strongly with UGT1A1-mediated bilirubin glucuronidation.

The T allele acts as a proxy marker for reduced-activity haplotypes at UGT1A1 — the enzyme responsible for ~95% of bilirubin conjugation in humans. Carrying one or two T alleles shifts the individual bilirubin setpoint upward, producing mildly elevated unconjugated bilirubin without liver damage. This condition, when sufficiently elevated, is termed Gilbert syndrome²² Gilbert syndrome
a benign constitutional hyperbilirubinemia affecting 3–10% of Western populations.

The Mechanism

The UGT1A cluster uses a unique splicing architecture: a shared promoter drives alternative exon 1 usage, so variants anywhere in the cluster can affect regulation of multiple family members simultaneously. rs6742078 lies 9,307 bp from the end of UGT1A10 and likely exerts its effects through linkage disequilibrium with functional variants in the UGT1A1 promoter or coding sequence — most prominently, the TA-repeat polymorphism (UGT1A1*28) and coding variants including Gly71Arg (rs4148323, UGT1A1*6). These functional variants reduce the enzyme's rate of bilirubin glucuronidation, causing unconjugated bilirubin to accumulate in plasma.

The downstream consequence in the biliary system is that elevated unconjugated bilirubin spills into bile at higher concentrations, exceeding its solubility threshold and promoting nucleation of calcium bilirubinate crystals³³ nucleation of calcium bilirubinate crystals
the seed particles that grow into black pigment gallstones. This is a dose-dependent chemical process: the higher the bilirubin, the greater the supersaturation of bile, and the greater the stone-formation risk.

The Evidence

Bilirubin levels: The landmark meta-analysis of 9,464 participants from three European cohorts⁴⁴ meta-analysis of 9,464 participants from three European cohorts
Johnson et al. Human Molecular Genetics, 2009 identified the UGT1A1 locus as the dominant genetic determinant of serum bilirubin, explaining ~18% of total variation — an exceptionally large proportion for a quantitative trait. The association p-value was <5×10⁻³²⁴, effectively impossible to obtain by chance. A subsequent GWAS in 10,282 Han Chinese⁵⁵ GWAS in 10,282 Han Chinese
Dai et al. Genetic Epidemiology, 2013 confirmed rs6742078 at combined P=1.44×10⁻⁸⁹, explaining 9.2% of bilirubin variation in East Asians.

Gallstone disease (causal, Mendelian randomization): Stender et al. JAMA Internal Medicine, 2013⁶⁶ Stender et al. JAMA Internal Medicine, 2013 used rs6742078 as a Mendelian randomization instrument in 61,212 Danish participants followed for up to 34 years. The T allele raised bilirubin by 16% per copy, with TT homozygotes averaging 90% higher bilirubin than GG homozygotes. Over 34 years, 3,374 participants developed symptomatic gallstone disease: GT heterozygotes had HR 1.09 (95% CI 1.02–1.17) and TT homozygotes HR 1.22 (95% CI 1.09–1.36) versus GG. Because Mendelian randomization uses a randomly assigned genetic instrument, these hazard ratios are interpreted as causal — elevated bilirubin itself is lithogenic, not merely a marker.

Sex-specific gallstone risk: Buch et al. Gastroenterology, 2010⁷⁷ Buch et al. Gastroenterology, 2010 found a striking sex difference in 2,606 German cases and 1,121 controls: male TT homozygotes had OR 2.34 (P=2.1×10⁻⁷) for gallstone disease, while women showed no significant association (P=0.47). The sex-specific finding replicated in South American samples (OR 2.19 in men, P=0.046; no effect in women). Combined, the UGT1A and ABCG8 loci attributed 21.2% of population- attributable risk in men. The biological basis of sex specificity is not fully understood, but oestrogen independently promotes cholesterol saturation in bile, potentially masking the bilirubin-mediated pathway in women while amplifying it in men who lack this alternative lithogenic mechanism.

Circulating cell-free DNA: An unanticipated finding from a GWAS of cell-free DNA levels⁸⁸ GWAS of cell-free DNA levels
Jylhävä et al. PLoS One, 2012 was that all 110 genome-wide significant SNPs for serum cf-DNA mapped to the UGT1A locus on 2q37, strongly implicating UGT1A1-associated glucuronidation pathways in the clearance of extracellular DNA from circulation.

Practical Actions

The TT genotype confers a clear, modifiable gallstone risk. Black pigment gallstones (the type driven by elevated unconjugated bilirubin) can cause biliary colic, cholecystitis, and pancreatitis when they obstruct the bile duct. Monitoring bilirubin and using targeted lifestyle and dietary measures to reduce gallstone nucleation is the evidence-based management approach.

For heterozygous GT carriers, the bilirubin increase (~16%) is modest. Awareness and periodic bilirubin monitoring during routine blood work is sufficient; no specific interventions are required unless other risk factors for gallstones are present.

Interactions

UGT1A1 coding variants (rs4148323): rs6742078 acts as a tag SNP for the broader UGT1A reduced-activity haplotype. Individuals who carry both rs6742078 T alleles and the UGT1A1*6 variant (rs4148323 A allele, common in East Asians) or UGT1A1*28 (rs887829, common in Europeans and Africans) have compounded reduction in bilirubin glucuronidation, producing more severe hyperbilirubinemia and greater gallstone risk. These combinations represent true Gilbert syndrome.

SLCO1B3 (rs2417940): This organic anion transporter on chromosome 12p12 handles hepatic uptake of bilirubin and other organic anions. In the same Chinese GWAS, rs2417940 explained an additional 0.9% of bilirubin variation. Combined reduced-activity genotypes at both loci may produce additive hyperbilirubinemia, though direct interaction data for this pair are limited.

The LDL receptor (LDLR) is the liver's primary tool for clearing low-density lipoprotein¹¹ low-density lipoprotein
LDL, the so-called "bad cholesterol," which ferries cholesterol through the bloodstream to tissues from the bloodstream. Mutations that disrupt LDLR function are the cause of familial hypercholesterolemia, one of the most common and dangerous inherited cardiovascular conditions. But you don't need a protein-changing mutation to impair LDLR function — rs688, a common polymorphism in exon 12, does it through a more subtle mechanism: altering how efficiently the LDLR gene's messenger RNA is spliced.

This variant — technically Asn591Asn (c.1773C>T) — causes no change to the protein sequence. The codon change (AAC→AAT) still encodes asparagine. Yet rs688 has measurable functional consequences on LDLR levels at the cell surface, LDL uptake, and ultimately plasma cholesterol. It represents a class of genetic variants increasingly recognized as important: synonymous variants that alter gene regulation rather than protein structure.

The Mechanism

LDLR pre-mRNA undergoes alternative splicing that can include or skip exon 12. When exon 12 is retained, the normal full-length LDLR receptor is produced. When it is skipped, a truncated, non-functional receptor is generated that is degraded by nonsense-mediated decay²² nonsense-mediated decay
NMD, a cellular quality-control mechanism that destroys mRNAs containing premature stop codons.

The rs688 C>T change neutralizes a putative exon splicing enhancer³³ putative exon splicing enhancer
ESE, a short sequence motif within the exon that recruits splicing factors to ensure the exon is included in the mature mRNA within exon 12. Without this enhancer signal, the splicing machinery is less likely to include exon 12 — reducing the fraction of LDLR mRNA that encodes functional receptor.

Gao et al. (2013)⁴⁴ Gao et al. (2013)
A common polymorphism in the LDL receptor gene has multiple effects on LDL receptor function, Human Molecular Genetics measured the downstream consequences in HepG2 liver cells: the minor (T) allele caused a 21.8% reduction in LDLR protein at the cell surface (P=0.012), a 25.7% increase in lysosomal mislocalization (P=0.037), and a 24.3% reduction in LDL uptake (P<0.01). The variant also impaired LDLR endosomal recycling and reduced binding to PCSK9, the regulator that controls LDLR degradation.

The splicing effect is quantified precisely: Lee et al. (2014)⁵⁵ Lee et al. (2014)
Mutual effect of rs688 and rs5925 in regulating low-density lipoprotein receptor splicing, DNA and Cell Biology showed that the T allele reduces exon 12 splicing efficiency by 9.36%±2.58% per allele. When combined with rs5925 (another LDLR polymorphism in the same haplotype block), the compound TT/TC haplotype produces the lowest splicing efficiency (68.54%±1.38%), compared to 79.60%±1.38% for the CC/CC haplotype.

This splicing reduction is also regulated by cellular sterol levels. Medina et al. (2011)⁶⁶ Medina et al. (2011)
Coordinately regulated alternative splicing of genes involved in cholesterol biosynthesis and uptake, PLoS One showed that cells normally increase LDLR exon 12 inclusion in response to low cholesterol — a feedback mechanism that boosts receptor production when cells need more cholesterol. In rs688 T allele carriers, this sterol-induced splicing regulation is blunted, impairing the body's ability to compensate for low-cholesterol states.

The Evidence

The clinical evidence connects splicing impairment to elevated LDL and cardiovascular risk. Zhu et al. (2007)⁷⁷ Zhu et al. (2007)
A common polymorphism decreases low-density lipoprotein receptor exon 12 splicing efficiency and associates with increased cholesterol, Human Molecular Genetics used the Framingham Offspring Study population to demonstrate that rs688 T allele carriers had approximately 10% higher total and LDL cholesterol than C allele homozygotes in pre-menopausal women. The effect was sex-dependent: it was absent or weak in men and post-menopausal women, suggesting that estrogen modulates the splicing mechanism or the downstream response to LDLR reduction.

Zou et al. (2008)⁸⁸ Zou et al. (2008)
Sex-dependent association of a common low-density lipoprotein receptor polymorphism with RNA splicing efficiency in the brain and Alzheimer's disease, Human Molecular Genetics found the opposite sex dependence in neural tissue: in brain samples from aged individuals, the T allele was associated with decreased LDLR exon 12 splicing efficiency specifically in males, not females. This tissue- and sex-dependent variation suggests the variant's effect depends on the splicing factor environment, which differs between liver and brain and varies with sex hormones.

At the cardiovascular disease level, a 2026 study from Bangladesh by Hossain et al.⁹⁹ Hossain et al.
Association of the rs688 Polymorphism in LDLR with Coronary Artery Disease, Genetics Research examined 225 participants (150 CAD patients, 75 controls) and found TT genotype carriers had 3.6-fold higher odds of coronary artery disease (OR=3.617, 95% CI: 1.089–10.05, P=0.035), with significantly elevated LDL cholesterol in TT and CT genotypes compared to CC. This study is limited by its small sample size and single-population design, but the direction of effect is consistent with the mechanistic evidence.

The GWAS Catalog records multiple genome-wide significant associations between rs688 and LDL and total cholesterol levels across large multi-ancestry studies (P=5×10⁻³⁰ for LDL, P=4×10⁻²⁸ for total cholesterol), confirming at population scale what the mechanistic studies show at the molecular level.

Practical Implications

The rs688 T allele is common — about 43% globally in European populations — so TT homozygosity (roughly 18% of Europeans) is not a rare finding. Unlike the rare LDLR mutations causing classical familial hypercholesterolemia, rs688 produces a modest per-allele effect. However, the magnitude of LDL elevation (~10% in susceptible individuals) is clinically relevant: a 10% LDL increase corresponds roughly to a 10-15% increase in cardiovascular event risk over a lifetime.

For TT homozygotes, the practical implications are earlier attention to lipid panels and consideration of lifestyle and pharmacological interventions at lower LDL thresholds than might be applied to the general population. The sex-dependent effects suggest pre-menopausal women carrying TT may be disproportionately affected and should be the highest-priority group for monitoring.

rs688 does not cause familial hypercholesterolemia and is classified as benign in ClinVar for that specific condition — meaning it is not a high-penetrance mutation that guarantees disease. It is best understood as a common functional variant that modestly shifts the LDL distribution upward and, at the population level, contributes meaningfully to cardiovascular risk.

Interactions

rs688 interacts with rs5925, another LDLR exon 12 polymorphism. The two variants regulate splicing cooperatively: the compound haplotype carrying both T alleles (rs688-T / rs5925-T) produces the lowest splicing efficiency (68.54%), while the C/C haplotype produces the highest (79.60%). When both variants are present in the same individual, the splicing deficit is additive.

LDLR splicing variants interact broadly with other cholesterol metabolism genes. Carriers of APOE ε4 (rs429358/rs7412) already face impaired LDL clearance due to apolipoprotein E binding differences; rs688-driven LDLR surface reduction compounds this deficit. PCSK9 gain-of-function variants (rs11590235) further reduce LDLR survival on the cell surface — rs688 TT homozygotes carrying a PCSK9 gain-of-function mutation face LDL reduction from two independent mechanisms simultaneously.

In individuals on statins: statins increase LDLR expression by inhibiting cholesterol synthesis and activating SREBP-mediated transcription. However, if rs688 simultaneously reduces the efficiency of LDLR pre-mRNA splicing, the net LDLR surface increase from statin therapy may be blunted relative to individuals with the CC genotype — an interaction worth exploring in pharmacogenomics research.

rs7454108 is a tag SNP¹¹ tag SNP
A genetic marker in near-perfect linkage disequilibrium with another variant, allowing it to serve as a proxy with >99% sensitivity and specificity that identifies the HLA-DQ8 haplotype with extraordinary precision. Located in the intergenic region²² intergenic region
DNA sequence between genes, often containing regulatory elements between HLA-DQB1 and HLA-DQA2 on chromosome 6, this SNP's C allele serves as a genetic "flag" for the presence of HLA-DQB1*03:02, the defining allele of the DQ8 haplotype. The HLA-DQ8 molecule is a heterodimer³³ heterodimer
A protein complex made of two different subunits encoded by DQA1*03:01 and DQB1*03:02, and its presence dramatically increases risk for two major autoimmune diseases: celiac disease and type 1 diabetes.

The Mechanism

The HLA (Human Leukocyte Antigen) system is the body's primary method for distinguishing self from non-self. HLA-DQ molecules sit on the surface of antigen-presenting cells⁴⁴ antigen-presenting cells
Specialized immune cells that display protein fragments to T cells, where they present protein fragments (peptides) to T cells for immune surveillance. HLA-DQ8 has a unique structural pocket that binds and presents gluten peptides from wheat, barley, and rye with high affinity, triggering an inappropriate immune response in susceptible individuals. Studies show⁵⁵ Studies show
Tollefsen et al. characterized DQ8-restricted gluten T cell epitopes and their deamidation requirements. J Clin Invest, 2006 that HLA-DQ8 molecules are particularly efficient at presenting immunodominant gliadin peptides after they've been deamidated⁶⁶ deamidated
Modified by the enzyme tissue transglutaminase, increasing immunogenicity by tissue transglutaminase.

For type 1 diabetes, HLA-DQ8 presents pancreatic β-cell autoantigens⁷⁷ pancreatic β-cell autoantigens
Self-proteins from insulin-producing cells including insulin, GAD65, and ZnT8 to autoreactive T cells. The highest risk genotype is DR3/4-DQ8 heterozygosity⁸⁸ heterozygosity
Carrying one copy of DQ2.5 (from DR3 haplotype) and one copy of DQ8 (from DR4 haplotype), which allows formation of a unique trans-encoded DQ molecule⁹⁹ trans-encoded DQ molecule
A DQ heterodimer formed by pairing alpha and beta chains from different chromosomes that further amplifies risk.

The Evidence

Monsuur et al. demonstrated¹⁰¹⁰ Monsuur et al. demonstrated
Effective detection of human leukocyte antigen risk alleles in celiac disease using tag single nucleotide polymorphisms. PLoS One, 2008 that rs7454108 identifies HLA-DQ8 carriers with 99.1% sensitivity and 99.6% specificity in European populations. This tag SNP is so reliable that it forms the basis of 23andMe's FDA-cleared¹¹¹¹ 23andMe's FDA-cleared
The first direct-to-consumer genetic health risk report cleared by the FDA celiac disease genetic risk report, analyzing rs7454108 alongside rs2187668 (the DQ2.5 tag) to identify the ~95% of celiac patients carrying permissive HLA genotypes.

A 2023 meta-analysis¹²¹² A 2023 meta-analysis
Meta-analysis and systematic review of HLA DQ2/DQ8 in adults with celiac disease. Int J Mol Sci, 2023 found HLA-DQ2 and/or DQ8 in over 95% of celiac disease patients across diverse populations, with HLA-DQ8 alone accounting for 5-10% of cases. In European populations, approximately 12% carry at least one copy of DQ8, but only 1% develop celiac disease, illustrating that HLA-DQ8 is necessary but not sufficient. Studies in siblings¹³¹³ Studies in siblings
Frequency of celiac disease and distribution of HLA-DQ2/DQ8 haplotypes among siblings of children with celiac disease. World J Clin Pediatr, 2022 show 10.7% prevalence among siblings of celiac patients—22.7 times the general population rate—with 98% of affected siblings carrying DQ2 and/or DQ8.

For type 1 diabetes, the evidence is even more dramatic. Barker et al.'s validation study¹⁴¹⁴ Barker et al.'s validation study
Two single nucleotide polymorphisms identify the highest-risk diabetes HLA genotype. Diabetes, 2008 in over 5,000 subjects from the Type 1 Diabetes Genetics Consortium found rs7454108 C allele present in 98.9% of individuals carrying DQB1*0302. The landmark PNAS study¹⁵¹⁵ The landmark PNAS study
Extreme genetic risk for type 1A diabetes. PNAS, 2006 by Aly et al. revealed that DR3/4-DQ8 siblings sharing both HLA haplotypes identical by descent¹⁶¹⁶ identical by descent
Inherited from the same parental chromosomes as their diabetic sibling with their diabetic proband had an 85% risk of developing islet autoantibodies by age 15, compared to 20% in those not sharing both haplotypes. Subsequent research¹⁷¹⁷ Subsequent research
Erlich et al. analysis of Type 1 Diabetes Genetics Consortium families confirmed DR4-DQ8 haplotype risk confirmed HLA-DRB1*04:01-DQB1*03:02 (DR4-DQ8) carries an odds ratio of 8.39 for type 1 diabetes.

Practical Implications

This SNP's primary clinical utility is in ruling out disease rather than predicting it. A TT genotype (no DQ8 copies) combined with absence of DQ2.5 makes celiac disease highly unlikely—approximately 98-99% negative predictive value. This can spare individuals from unnecessary small bowel biopsies¹⁸¹⁸ small bowel biopsies
Gold standard diagnostic procedure requiring endoscopy and tissue sampling when celiac disease is being considered. However, carrying one or two C alleles does not mean you will develop these conditions—it simply means you're genetically eligible.

For celiac disease, environmental factors matter enormously: gluten exposure timing in infancy, gut microbiome composition, and viral infections¹⁹¹⁹ viral infections
Particularly enteroviruses, which may trigger loss of oral tolerance to gluten may all influence whether genetic risk translates to active disease. For type 1 diabetes, additional non-HLA genes (insulin gene VNTR, PTPN22, CTLA4) and environmental triggers work in concert with HLA risk.

If you carry HLA-DQ8 and have first-degree relatives with celiac disease or type 1 diabetes, or if you experience unexplained symptoms²⁰²⁰ symptoms
Chronic diarrhea, bloating, iron-deficiency anemia, fatigue, weight loss for celiac; excessive thirst, frequent urination, unexplained weight loss for type 1 diabetes, genetic testing combined with serological screening (tissue transglutaminase antibodies for celiac, islet autoantibodies for type 1 diabetes) is warranted.

Interactions

The most clinically significant interaction is between rs7454108 (HLA-DQ8 tag) and rs2187668 (HLA-DQ2.5 tag). Individuals who are compound heterozygous²¹²¹ compound heterozygous
Carrying one copy each of DQ2.5 and DQ8 face heightened risk for both celiac disease and type 1 diabetes compared to carrying either haplotype alone. For celiac, this DQ2.5/DQ8 combination is second only to DQ2.5 homozygosity in risk magnitude. For type 1 diabetes, the DR3/4-DQ8 genotype (tagged by rs2187668 heterozygous + rs7454108 heterozygous) represents the highest genetic risk, accounting for 30-50% of childhood-onset cases. The trans-encoded DQ molecule²²²² trans-encoded DQ molecule
DQA1*05:01 from DR3 paired with DQB1*03:02 from DR4 formed in DR3/4-DQ8 individuals may have unique peptide-binding properties that amplify autoimmune risk beyond the sum of individual haplotypes.

A compound implication should be created for individuals carrying both DQ2.5 (rs2187668 CT or TT) and DQ8 (rs7454108 CT or CC), as the combined genotype warrants earlier and more intensive screening for both celiac disease and type 1 diabetes, particularly in individuals with affected family members or suggestive symptoms. The recommendation would be periodic serological screening and heightened clinical vigilance, rather than the "unlikely to develop disease" reassurance appropriate for individuals lacking both risk haplotypes.

Your body's ability to absorb iron from food is not just about what you eat — it is tightly controlled by a hormonal gatekeeper called hepcidin¹¹ hepcidin
A 25-amino-acid peptide hormone produced by the liver that acts as the master regulator of systemic iron homeostasis. Hepcidin blocks ferroportin²² ferroportin
The only known mammalian cellular iron exporter, present on the surface of enterocytes (gut lining cells) and macrophages, the only iron export channel on gut cells, effectively slamming the door on iron absorption when levels are sufficient. The TMPRSS6 gene encodes matriptase-2³³ matriptase-2
A type II transmembrane serine protease expressed primarily in the liver, a liver enzyme whose job is to keep hepcidin in check by cleaving hemojuvelin⁴⁴ hemojuvelin
A membrane-bound co-receptor that activates the BMP/SMAD signaling pathway, which drives hepcidin transcription on the cell surface. When matriptase-2 works well, hepcidin stays low and iron flows freely from the gut into the bloodstream. When it does not, hepcidin rises and iron absorption drops.

The Ala736Val variant (rs855791) sits in the catalytic domain of matriptase-2 — the business end of the enzyme. The A allele (Val736) reduces the enzyme's ability to suppress hepcidin, resulting in higher hepcidin levels and lower iron absorption. This is not a rare mutation causing disease. It is a common polymorphism carried by roughly half of Europeans and over half of East Asians, making it the single strongest common genetic determinant of iron status identified by genome-wide association studies.

The Mechanism

Matriptase-2 normally cleaves hemojuvelin from the liver cell surface, disabling the BMP/SMAD signaling pathway⁵⁵ BMP/SMAD signaling pathway
Bone morphogenetic protein / son of mothers against decapentaplegic — a signaling cascade that drives hepcidin gene transcription in hepatocytes that drives hepcidin production. The Val736 form of matriptase-2 is less efficient at this cleavage. In vitro experiments⁶⁶ In vitro experiments
Nai A et al. TMPRSS6 rs855791 modulates hepcidin transcription in vitro and serum hepcidin levels in normal individuals. Blood, 2011 demonstrated that cells expressing the Ala736 form suppress hepcidin transcription more effectively than those expressing Val736. In living people, this translates to measurable differences: Ala736 homozygotes have lower serum hepcidin, higher transferrin saturation, and higher serum iron compared to Val736 homozygotes.

The downstream consequence is straightforward. Higher hepcidin means more ferroportin gets internalized and degraded on gut enterocytes. Less ferroportin means less iron crosses from the gut lining into the bloodstream. The effect is dose-dependent — each copy of the A allele (Val736) incrementally raises hepcidin and lowers iron absorption.

The Evidence

Two landmark genome-wide association studies published simultaneously in 2009 identified rs855791 as the top hit for iron-related traits. Benyamin et al.⁷⁷ Benyamin et al.
Benyamin B et al. Common variants in TMPRSS6 are associated with iron status and erythrocyte volume. Nat Genet, 2009 found associations with serum iron (P = 1.5 x 10^-20), transferrin saturation (P = 2.2 x 10^-23), and mean corpuscular volume (P = 1.1 x 10^-10). Each copy of the risk allele decreased serum iron and transferrin saturation by 0.18 and 0.20 standard deviations respectively, explaining about 2% of population variance in these traits. Chambers et al.⁸⁸ Chambers et al.
Chambers JC et al. Genome-wide association study identifies variants in TMPRSS6 associated with hemoglobin levels. Nat Genet, 2009 reported that each A allele copy lowered hemoglobin by 0.13 g/dL, with AA homozygotes averaging 0.2 g/dL lower hemoglobin than GG homozygotes.

A stable iron isotope study⁹⁹ stable iron isotope study
Buerkli S et al. The TMPRSS6 variant (SNP rs855791) affects iron metabolism and oral iron absorption — a stable iron isotope study in Taiwanese women. Haematologica, 2021 directly measured iron absorption using labeled iron meals. At equivalent low iron stores (ferritin 15 ug/L), women with the CC genotype (Ala/Ala on the coding strand, GG on 23andMe) absorbed 26.6% of the iron dose, while TT women (Val/Val, AA on 23andMe) absorbed only 18.5% — a roughly 30% reduction in iron absorption capacity.

A systematic review¹⁰¹⁰ systematic review
Gichohi-Wainaina WN et al. Inter-ethnic differences in genetic variants within the transmembrane protease, serine 6 (TMPRSS6) gene associated with iron status indicators. Genes Nutr, 2015 confirmed that the A allele is consistently associated with approximately 0.11 g/dL lower hemoglobin across populations.

Practical Implications

For people with the AA genotype who already have adequate iron stores, this variant is clinically silent. The effect matters most when iron demand is high or dietary intake is marginal — during menstruation, pregnancy, rapid growth, vegetarian or vegan diets, or endurance athletics. In these contexts, a 30% reduction in absorption efficiency can tip the balance toward deficiency.

Iron absorption can be optimized by pairing iron-rich foods with vitamin C, choosing heme iron sources¹¹¹¹ heme iron sources
Heme iron from meat, poultry, and fish is absorbed 2-3 times more efficiently than non-heme iron from plants, and its absorption is less affected by hepcidin when possible, and avoiding calcium, tea, and coffee at iron-containing meals. For those who need supplements, iron bisglycinate¹²¹² iron bisglycinate
A chelated form of iron that is absorbed via a different pathway (peptide transporters) and is less affected by hepcidin-mediated ferroportin degradation may be preferable to ferrous sulfate because it is partially absorbed through peptide transporters rather than ferroportin alone.

Monitoring is simple: a serum ferritin test (ideally with transferrin saturation) tells you whether your iron stores are adequate. A ferritin below 30 ug/L suggests depleted stores even if hemoglobin is still normal.

Interactions

TMPRSS6 rs855791 interacts with rs4820268, another TMPRSS6 variant in linkage disequilibrium that independently affects iron parameters. More importantly, it interacts with HFE variants¹³¹³ HFE variants
HFE encodes a protein that also regulates hepcidin. The C282Y (rs1800562) and H63D (rs1799945) variants in HFE cause hereditary hemochromatosis by reducing hepcidin, leading to iron overload. In hereditary hemochromatosis (HFE C282Y homozygotes), the Val736 allele of TMPRSS6 acts as a protective modifier — its hepcidin-raising effect partially counteracts the hepcidin-lowering effect of HFE mutations, and Val736 carriers show reduced risk of cirrhosis¹⁴¹⁴ Val736 carriers show reduced risk of cirrhosis
Valenti L et al. Effect of the A736V TMPRSS6 polymorphism on the penetrance and clinical expression of hereditary hemochromatosis. J Hepatol, 2012 and hepatocellular carcinoma compared to Ala736 homozygotes.

Conversely, carrying both the AA genotype at rs855791 and being a menstruating woman, a vegetarian, or an endurance athlete compounds iron loss risk — these are the individuals most likely to benefit from proactive monitoring and dietary optimization.

Interleukin-13¹¹ Interleukin-13
IL-13 is a Th2 cytokine secreted by mast cells, basophils, ILC2 innate lymphoid cells, and activated CD4+ T cells; it drives IgE class switching, mucus hypersecretion, skin barrier remodeling, and airway smooth-muscle hyperresponsiveness is one of the most potent mediators of allergic inflammation in humans. While the better-known rs20541 variant changes the amino acid sequence of the IL-13 protein (p.Arg130Gln), rs1295685 sits 481 base pairs downstream at position chr5:132660753 in the 3' untranslated region (UTR) of the IL13 gene. It does not alter the protein — instead, it lies in a region of the mRNA that controls how long the transcript persists in cells and how efficiently it is translated. These 3'-UTR regulatory variants can influence gene expression as powerfully as coding changes, particularly for cytokines like IL-13 whose secretion is tightly gated by post-transcriptional regulation.

The Mechanism

The 3'-UTR of mRNA contains binding sites for microRNAs and RNA-binding proteins that collectively determine transcript stability and translation rate. A single-nucleotide variant in this region can disrupt or create a microRNA binding site, shifting the equilibrium of IL-13 production upward or downward across immune cells. rs1295685 lies within the IL13 3'-UTR on the plus strand (GRCh38 chr5:132660753), where the minor A allele is the GRCh38 reference but the population-major G allele (~80% globally) represents the baseline regulatory configuration. The A allele — present in approximately 20% of European chromosomes — is found almost exclusively on the same haplotype as the rs20541 Q130 risk allele, confirmed by haplotype analysis in Japanese cohorts²² haplotype analysis in Japanese cohorts
Lee et al. Ann Allergy Asthma Immunol 2020; fine-mapping of IL13 in 495 cases and 444 controls with independent replication in 757 cases and 1,620 controls; rs1295685 showed P=0.01 for AD association in the pilot study. This strong linkage disequilibrium means the two variants tag the same risk haplotype block rather than independently affecting IL-13 biology. The clinical consequence of carrying the A allele is the same as for rs20541-A: higher constitutive IL-13 pathway activity, measurably elevated serum IgE, and greater lifetime risk for atopic disease.

The Evidence

The IL13 5q31 locus is one of the most consistently replicated genomic regions in allergy genetics. A 2023 European and multi-ancestry GWAS meta-analysis³³ 2023 European and multi-ancestry GWAS meta-analysis
Budu-Aggrey et al., Nature Communications; European discovery: ~21,000 AD cases and ~95,000 controls; 23andMe replication: 2.9 million individuals placed the 5q31 IL13 locus at P<10⁻³⁶ for atopic dermatitis, one of the strongest genetic signals in all of human atopy genetics. rs1295685 sits within this implicated haplotype block. Fine-mapping work in [Japanese AD cohorts (495 cases, 444 controls pilot; 757 cases, 1,620 controls replication) | Lee et al. 2020](https://pubmed.ncbi.nlm.nih.gov/32371243/) established that both rs20541 and rs1295685 are significantly associated with atopic dermatitis, and that haplotypes containing both variants confer disease risk (minimum P=0.006). The same study confirmed strong LD between these two IL13 variants, locating the primary functional driver within the rs20541 coding change while acknowledging that rs1295685 marks the same risk haplotype. Fine-mapping of serum IgE loci in [>1,300 German children | Sharma et al. Allergy 2014](https://pubmed.ncbi.nlm.nih.gov/24930997/⁴⁴ https://pubmed.ncbi.nlm.nih.gov/24930997/) confirmed the 5q31 region — containing both IL13 variants — as a major susceptibility locus for elevated total serum IgE, the primary biological readout of sustained IL-13-driven B-cell class-switching.

Because rs1295685 is a 3'-UTR variant, it may also have a regulatory contribution that is independent of rs20541 at the mRNA level — 3'-UTR polymorphisms in cytokine genes frequently modulate transcript stability and production kinetics in ways that complement coding changes. However, the current evidence does not permit separating a 3'-UTR-specific regulatory effect from haplotype tagging; both mechanisms may contribute.

Practical Implications

The clinical implications of carrying the rs1295685 A allele are directly parallel to those of rs20541-A, because the variants co-segregate on the same haplotype in nearly all carriers. Elevated serum IgE, heightened susceptibility to atopic dermatitis, allergic rhinitis, and eczema, and a greater tendency to mount Th2 responses to environmental allergens are the principal consequences. For carriers with active atopic disease inadequately controlled by topical therapies, IL-13-pathway biologics (tralokinumab, dupilumab) represent a genetically rationale treatment pathway. Measuring serum total IgE and periostin provides a quantitative readout of how biologically active the IL-13 pathway is in the individual carrier, and documents eligibility for biologic therapy.

Interactions

rs1295685 lies in strong LD with rs20541 (IL13 R130Q) — these two variants tag the same risk haplotype. Carriers of the A allele at rs1295685 almost invariably also carry the A allele at rs20541, so the combined functional consequence represents compound within-gene effects on IL-13: one variant alters the protein surface charge (rs20541), the other potentially alters mRNA stability and translation rate (rs1295685).

The rs1801275 variant (IL-4Rα R576Q) alters the shared IL-4Rα signal transduction subunit used by both IL-4 and IL-13 receptors. Individuals carrying both rs1295685-A (IL13 UTR risk haplotype) and rs1801275 risk allele may face additive Th2 dysregulation — enhanced IL-13 production meeting altered receptor signal transduction — a mechanistic interaction relevant to dupilumab pharmacogenomics, since dupilumab targets IL-4Rα directly.

The rs2040704 variant in RAD50/TH2LCRR upstream of IL13 tags an enhancer hub that coordinates IL-4, IL-5, and IL-13 expression. Carriers of rs1295685-A alongside the rs2040704 risk haplotype may face compounding Th2 amplification via both cisregulatory (enhancer-level) and UTR-level effects on IL-13 expression.

The TMPRSS3 gene encodes a type II transmembrane serine protease¹¹ type II transmembrane serine protease
Anchored to the cell membrane with its catalytic domain facing the extracellular space; expressed in cochlear inner hair cells, outer hair cells, spiral ganglion neurons, and the stria vascularis essential for the survival and maturation of cochlear hair cells. TMPRSS3 is unusual among serine proteases in that it undergoes autocatalytic activation — the full-length single-chain zymogen must cleave itself at a specific arginine residue to release the active catalytic domain. The p.Arg216Leu substitution strikes this cleavage site directly, converting the critical arginine to leucine and locking the protein permanently in its inactive zymogen form.

This variant was identified in two Turkish brothers with non-syndromic deafness born to consanguineous parents²² identified in two Turkish brothers with non-syndromic deafness born to consanguineous parents
Wattenhofer M et al., Human Genetics 2005, screening 25 Turkish families; R216L found homozygous in the affected siblings; the mutation was the highest-scoring TMPRSS3 mutation for LOD score linkage to chr21q22.3 in that cohort. It is catalogued in ClinVar (variation 4946) as pathogenic for autosomal recessive nonsyndromic hearing loss 8 (DFNB8), with OMIM allelic entry 605511.0005.

The Mechanism

TMPRSS3 is synthesized as an inactive single-chain precursor (zymogen). Activation requires autocatalytic cleavage at arginine 216³³ arginine 216
The canonical serine protease activation motif contains a conserved arginine or lysine immediately preceding the catalytic domain; cleavage here releases the prodomain and exposes the active-site triad, which generates the active two-chain form held together by a disulfide bond. This processing step is obligatory for all downstream activity.

The p.Arg216Leu substitution replaces the cleavage-site arginine with leucine — an amino acid that the protease cannot recognize as a cleavage substrate. Functional characterization in Xenopus oocytes⁴⁴ Functional characterization in Xenopus oocytes
Wattenhofer 2005 used the well-validated oocyte expression system to measure both autocatalytic processing and ENaC activation; neither occurred with R216L TMPRSS3 confirmed that the R216L mutant protein: (1) fails to undergo proteolytic self-cleavage, and (2) is completely unable to activate the epithelial sodium channel (ENaC). This distinguishes R216L from hypomorphic missense variants (such as p.Ala306Thr, which retains partial activity) — R216L produces a functional null.

The downstream cochlear consequence is hair cell degeneration. In mouse models, Tmprss3-deficient cochleae show normal morphology at birth but undergo rapid progressive hair cell loss beginning at postnatal day 12⁵⁵ Tmprss3-deficient cochleae show normal morphology at birth but undergo rapid progressive hair cell loss beginning at postnatal day 12
The onset coincides exactly with the moment hearing activates in mice; loss begins in the high-frequency basal cochlear turn and sweeps toward the apex, consistent with the down-sloping audiogram seen in human DFNB8 — the same postnatal timing when the organ of Corti first becomes mechanically and electrically active.

The Evidence

Functional evidence is conclusive. The 2005 Wattenhofer study provided direct biochemical proof that R216L abolishes TMPRSS3 activity through loss of autocatalytic processing. This is one of only a handful of TMPRSS3 variants with complete functional nullification confirmed in a heterologous expression system⁶⁶ This is one of only a handful of TMPRSS3 variants with complete functional nullification confirmed in a heterologous expression system
Most TMPRSS3 missense variants have not been functionally characterized; R216L and p.Ala306Thr are the best-characterized variants in the literature.

Population context. TMPRSS3 accounts for approximately 11% of autosomal recessive nonsyndromic hearing loss in Turkish populations⁷⁷ TMPRSS3 accounts for approximately 11% of autosomal recessive nonsyndromic hearing loss in Turkish populations
Compared to <1% in Caucasians, 0.7% in Japanese, 3% in Pakistani, 4.6% in Chinese, 5–6% in Tunisian, and 5.9% in Korean populations — Turkish prevalence is the highest documented, making it the highest-prevalence population for this gene. The R216L allele was specifically characterized in a Turkish family, and given the high TMPRSS3 burden in Turkish populations, this allele likely contributes to a meaningful fraction of Turkish ARNSHL cases. In gnomAD, the A allele at chr21:42383168 (the R216L plus-strand allele) appears at a global frequency of approximately 0.003% — consistent with a rare recessive pathogenic allele maintained at low frequency by heterozygous carrier state.

Genotype-phenotype correlation. A comprehensive genotype-phenotype analysis⁸⁸ comprehensive genotype-phenotype analysis
Nisenbaum et al. Audiology & Neurotology 2023, reviewing all published TMPRSS3 cases with natural history data established that biallelic severe/null TMPRSS3 alleles produce prelingual profound deafness (DFNB10), while combinations of one null allele with one missense allele typically produce postlingual progressive hearing loss (DFNB8) with a characteristic down-sloping audiogram progressing at approximately 0.3 dB per year⁹⁹ 0.3 dB per year
This rate applies to DFNB8 phenotype; DFNB10 patients present with congenital profound deafness and show essentially no residual cochlear function by audiometric testing. Because R216L is a functional null, homozygous R216L individuals would be expected to manifest DFNB10 (congenital profound deafness), while compound heterozygotes carrying R216L on one allele and a milder missense variant on the other might present with DFNB8 progressive loss.

Cochlear implantation outcomes in TMPRSS3-related hearing loss are excellent and consistent across populations¹⁰¹⁰ excellent and consistent across populations
International cohort of 127 patients, 16 centers, 6 countries; mean word recognition score 76% at follow-up. Age at implantation — not genotype — is the principal predictor of speech recognition outcome, with each year of delay associated with a measurable decrement in outcome. This makes early diagnosis and timely implantation the most critical clinical interventions.

Practical Implications

For confirmed homozygous (AA) individuals, this information directly supports early hearing intervention. For heterozygous (AC) carriers, hearing is expected to be normal but carrier status is clinically important for reproductive planning, particularly given the elevated TMPRSS3 carrier frequency in Turkish and other Middle Eastern populations.

For any individual with this variant, standard hearing health practices do not require modification — TMPRSS3-related hearing loss does not respond to dietary, supplement, or pharmacological interventions. The clinical value is entirely in diagnosis (confirming the cause of hearing loss in affected individuals), prognosis (predicting progression), and reproductive counseling (assessing offspring risk in carrier couples).

Interactions

The primary interaction is with other TMPRSS3 pathogenic alleles. Biallelic TMPRSS3 mutations can arise from homozygosity (two copies of the same allele, as in the original Turkish family carrying two R216L copies) or compound heterozygosity (one copy of R216L on one chromosome and a different pathogenic allele on the other). Given the diversity of TMPRSS3 pathogenic alleles documented across populations — including rs727503493 (c.208delC frameshift) and rs45598239 locus variants — comprehensive TMPRSS3 panel sequencing is required to identify compound heterozygotes, who will have two different pathogenic alleles.

A possible digenic interaction with GJB2¹¹¹¹ A possible digenic interaction with GJB2
GJB2 encodes connexin 26, the most common cause of ARNSHL in Caucasians (c.35delG allele, rs80338939); initial case reports suggested TMPRSS3/GJB2 digenic inheritance, later disputed by larger series has been proposed but is not confirmed. In clinical practice, when a single TMPRSS3 pathogenic allele is found in an individual with hearing loss, comprehensive deafness gene panel testing — including GJB2 — is warranted.

HNF4A (Hepatocyte Nuclear Factor 4 Alpha) is a master transcription factor that controls hundreds of genes in pancreatic beta cells and the liver. Unlike the common polygenic variants that nudge diabetes risk by a few percent, a pathogenic variant in HNF4A rewrites your entire metabolic trajectory¹¹ rewrites your entire metabolic trajectory
HNF4A sits at the top of a transcription factor cascade: it regulates HNF1A, which regulates genes needed for glucose-stimulated insulin secretion. This is MODY1 — Maturity-Onset Diabetes of the Young, type 1 — and it follows a trajectory unlike any common form of diabetes: paradoxical hyperinsulinism at birth, followed by progressive insulinopenia in adulthood.

The Mechanism

The c.763C>T variant introduces a premature stop codon at position 277 (p.Gln277Ter), truncating the protein and deleting the C-terminal 187 amino acids. The truncated protein loses its transcriptional transactivation activity — it cannot dimerize, cannot bind DNA, and cannot activate target genes²² cannot dimerize, cannot bind DNA, and cannot activate target genes
Stoffel & Duncan 1997 showed the Q268X truncated protein had no DNA-binding activity in reporter assays and failed to transactivate HNF4A target genes. Because HNF4A is required for normal transcription of genes driving glucose-stimulated insulin secretion in pancreatic beta cells, haploinsufficiency — one functional copy instead of two — causes progressive loss of beta-cell response to glucose.

The temporal paradox is striking: in the fetal and neonatal period, the same mutation causes excessive insulin secretion³³ same mutation causes excessive insulin secretion
Mice with beta-cell deletion of Hnf4a show hyperinsulinism in utero and hyperinsulinemic hypoglycemia at birth, confirming the mechanism, producing macrosomia and neonatal hypoglycemia. Over years, beta-cell capacity declines progressively, and insulinopenic diabetes emerges — usually in the second or third decade of life.

The Evidence

The landmark 1996 study by Yamagata et al.⁴⁴ landmark 1996 study by Yamagata et al.
Yamagata K et al. Mutations in the hepatocyte nuclear factor-4alpha gene in maturity-onset diabetes of the young (MODY1). Nature, 1996 identified HNF4A as the gene responsible for MODY1 in the historic RW pedigree — a six-generation Michigan family with 74 affected members studied prospectively since 1958. The Q268X mutation (equivalent to Q277X on current reference transcripts) was the founding pathogenic variant in this family.

The neonatal phenotype was quantified by Pearson et al. in 107 HNF4A mutation carriers⁵⁵ Pearson et al. in 107 HNF4A mutation carriers
Pearson ER et al. Macrosomia and hyperinsulinaemic hypoglycaemia in patients with heterozygous mutations in the HNF4A gene. PLOS Medicine, 2007: 56% of carriers were macrosomic (mean birth weight 4,450 g), a median 790 g heavier than unaffected siblings (p<0.001). Transient neonatal hypoglycemia occurred in 15% of carriers — versus none of the unaffected family members.

For treatment, Crowley et al. 2025⁶⁶ Crowley et al. 2025
Crowley MT et al. Sulphonylurea efficacy and end-organ outcomes in the management of HNF4A-MODY. Diabetic Medicine, 2025 followed HNF4A-MODY patients on sulfonylurea monotherapy for six years: 51.6% achieved significant HbA1c reduction (p=0.045), with responders maintaining HbA1c at 45 mmol/mol (6.3%) compared to 58 mmol/mol (7.5%) before treatment. Responders tended to be younger with shorter disease duration — arguing for early diagnosis and early initiation.

Mirshahi et al. 2022⁷⁷ Mirshahi et al. 2022
Mirshahi UL et al. Reduced penetrance of MODY-associated HNF1A/HNF4A variants but not GCK variants in clinically unselected cohorts. Am J Hum Genet, 2022 found that penetrance varies dramatically by discovery context: 98% in clinical referral cohorts by age 40, but only 5–17% in population health system cohorts. This means that an HNF4A pathogenic variant found incidentally in a healthy adult carries lower disease probability than the same variant found in a referred diabetic patient — context matters for counseling.

Practical Actions

The most important single thing a carrier can do: obtain a definitive genetic diagnosis and discuss transition to sulfonylurea therapy with a specialist in monogenic diabetes. Sulfonylureas bypass the impaired glucose-stimulated insulin secretion by directly stimulating the KATP channel in beta cells — they work where the genetic defect cannot. HNF4A-MODY patients often respond dramatically better to low-dose sulfonylurea than to insulin.

Pregnancy requires special management: glibenclamide crosses the placenta at ~70% of maternal levels, amplifying the genetic tendency toward macrosomia and neonatal hypoglycemia. Women on sulfonylurea should transition to insulin before conception or by the second trimester. Neonatal glucose monitoring is mandatory for all newborns of HNF4A carriers, regardless of the father's or mother's glycemic control.

Family screening is strongly indicated: with 50% inheritance probability and high penetrance in the clinical setting, first-degree relatives of a confirmed MODY1 carrier should all have genetic testing offered.

Interactions

HNF4A sits directly upstream of HNF1A (MODY3) in the transcription factor hierarchy — HNF4A activates HNF1A transcription, and HNF1A in turn regulates many of the same beta-cell function genes. Rare patients carry pathogenic variants in both HNF4A and HNF1A (digenic MODY), presenting with earlier onset and more severe disease than either mutation alone. If a first-degree relative has a known HNF1A pathogenic variant, combined panel testing covering HNF4A, HNF1A, GCK, HNF1B, and other MODY genes is preferred over single-gene testing.

The MTRR gene (methionine synthase reductase) runs a critical maintenance reaction in the methylation cycle. Methionine synthase (MTR) converts homocysteine back to methionine using vitamin B12 as a cofactor, but in doing so it oxidizes its own cobalamin ¹¹ Cobalamin: the cobalt-containing form of vitamin B12 that acts as the cofactor for MTR cofactor to an inactive form. MTRR's sole job is to reactivate this oxidized B12, keeping MTR running. If MTRR works less efficiently, MTR stalls and homocysteine accumulates — but only when B12 supply is tight.

The Mechanism

The S175L missense variant (c.524C>T) substitutes a serine for leucine at position 175 of the MTRR protein. Serine and leucine differ significantly in polarity: serine is hydrophilic, leucine is hydrophobic. Position 175 lies in a functional domain of MTRR, and the amino acid swap is thought to reduce the enzyme's efficiency at reactivating the cobalamin cofactor. Critically, this effect is only unmasked when intracellular B12 is in short supply — when B12 is adequate, the pathway appears to compensate. Riboflavin (vitamin B2) is also a cofactor for MTRR via its FMN ²² Flavin mononucleotide — the active form of riboflavin used as an electron carrier in MTRR domain, so riboflavin status modulates the variant's downstream impact.

The Evidence

The clearest data on rs1532268 comes from a Spanish population study of 771 adults³³ Spanish population study of 771 adults
García-Minguillán CJ et al. Riboflavin status modifies the effects of MTHFR and MTRR polymorphisms on homocysteine. Genes Nutr, 2014. T-allele carriers had 13.7% higher plasma homocysteine when cobalamin was low (≤273 pmol/L, lowest quartile) compared to CC individuals (p < 0.01). When cobalamin was in the upper quartiles, no difference was observed. This gene–environment interaction identifies the key lever: B12 status.

For cancer risk, a meta-analysis of five studies pooling 2800 gastric cancer cases and 2679 controls⁴⁴ meta-analysis of five studies pooling 2800 gastric cancer cases and 2679 controls
Zhong G et al. MTRR rs1532268 polymorphism and gastric cancer risk. J Int Med Res, 2022 found the T allele increases gastric cancer risk by approximately 14% (OR 1.14, 95% CI 1.01–1.29). A separate Korean case-control study⁵⁵ Korean case-control study
Lu YT et al. Riboflavin intake, MTRR genetic polymorphism rs1532268 and gastric cancer risk. Br J Nutr, 2022 (377 cases, 756 controls) showed that T-allele carriers with low riboflavin intake had 93% higher gastric cancer risk (OR 1.93, 95% CI 1.09–3.42), while adequate riboflavin appeared protective.

For drug interactions, pediatric ALL patients with the CT or TT genotype showed significantly higher methotrexate serum concentrations⁶⁶ significantly higher methotrexate serum concentrations
PMID 35434830 at 24 hours than CC patients (p = 0.04), suggesting altered folate pathway pharmacokinetics that may affect toxicity monitoring.

Practical Actions

The actionable insight from this variant is B12-centric: maintaining adequate cobalamin removes the functional penalty of the T allele. Methylcobalamin — the active form that directly participates in the MTR-MTRR cycle — is the preferred supplemental form. Riboflavin status also matters; T-allele carriers on low riboflavin diets face compounded gastric cancer risk, and riboflavin is a cheap, safe supplement. Periodic monitoring of plasma homocysteine provides a functional readout of whether the methylation cycle is running smoothly.

Interactions

MTRR S175L sits directly upstream of MTR (rs1805087, A2756G), which it reactivates. If both MTR and MTRR are running suboptimally, the homocysteine-to-methionine conversion is compromised from two directions simultaneously. MTHFR (rs1801133, C677T) is an upstream pathway partner supplying the methyl-THF substrate for MTR; compound impairment across MTHFR + MTRR + MTR (the "methylation triple") represents the strongest case for targeted B-vitamin supplementation in this pathway. MTRR A66G (rs1801394) is the most studied MTRR variant and is well-established as a functional variant; rs1532268 likely acts independently given its location in a different exon.